# EDGAR Filing Document

**Accession Number:** 0001418477
**File Stem:** 0001654954-23-002543
**Filing Date:** 2023-3
**Character Count:** 6485
**Document Hash:** ab0b8783446819f6d76d3e53d396bd76
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-002543.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001654954-23-002543

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230306

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LASANTA PEDRO J
- **CENTRAL INDEX KEY:** 0001418477

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50956
- **FILM NUMBER:** 23716418

**MAIL ADDRESS:**
- **STREET 1:** 373 MENDEZ VIGO
- **STREET 2:** STE 110
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646

**FORMER NAME:**
- **FORMER CONFORMED NAME:** LASANT PEDRO J
- **DATE OF NAME CHANGE:** 20071114
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharma-Bio Serv, Inc.
- **CENTRAL INDEX KEY:** 0001304161
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **IRS NUMBER:** 200653570
- **FISCAL YEAR END:** 1031

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646
- **BUSINESS PHONE:** 787-278-2709

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAWRENCE CONSULTING GROUP INC
- **DATE OF NAME CHANGE:** 20040923

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LASANTA PEDRO J<br><sub>(Last) (First) (Middle)</sub><br>6 ROAD 696<br><sub>(Street)</sub><br>DORADO, PR 00646<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Pharma-Bio Serv, Inc. [ PBSV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-06 |  | M |  | 100000 | A | $0.88 | 194552 | D |  |
| Common Stock | 2023-03-06 |  | F |  | 76522<sup>(1)</sup> | D | $1.15 | 118030 | D |  |
| Common Stock | 2023-03-06 |  | M |  | 8325 | A | $0.99 | 126355 | D |  |
| Common Stock | 2023-03-06 |  | F |  | 7167<sup>(1)</sup> | D | $1.15 | 119188 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $0.88 | 2023-03-06 |  | M |  |  | 100000 | <sup>(2)</sup> | 2024-10-04 | Common Stock | 100000 | $0 | 0 | D |  |
| Stock Option | $0.99 | 2023-03-06 |  | M |  |  | 8325 | <sup>(3)</sup> | 2026-12-09 | Common Stock | 8325 | $0 | 16675 | D |  |

---

### Footnotes:

(1) Represents the aggregate amount of shares of Common Stock withheld for a cashless exercise.

(2) The stock option vested in three equal annual installments beginning on October 4, 2020.

(3) On December 9, 2021, the reporting person was granted a stock option to purchase 25,000 shares, which stock option vests in three equal installments beginning on December 9, 2022.

**Signature:** /s/ Pedro J. Lasanta  
**Date:** 2023-03-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**